Subscribe Us

header ads

Recents

header ads

Nanomedicine Market Size, Growth, Demands Outlook and Forecasts to 2030

Precedence Research - January 31, 2023

According to the research report, the global nanomedicine market size is expected to touch USD 964.15 Billion by 2030, from USD 417.65 Billion in 2022, growing with a significant CAGR of 11% from 2022 to 2030. 

Nanomedicine Market Size, Statistics 2021 to 2030 

The nanomedicine report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global nanomedicine in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global nanomedicine market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global nanomedicine during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1633

 Report Scope of the Nanomedicine Market

Report CoverageDetails
Market Size by 2030USD 964.15 Billion
Growth Rate from 2022 to 2030

CAGR of 11%

Largest MarketNorth America
Fastest Growing MarketAsia Pacific
Base Year2021
Forecast Period2022 to 2030
Segments CoveredModality, Application, Indication, Nanomolecule Type, Geography

This study covers a detailed segmentation of the global nanomedicine market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global nanomedicine market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

  • Sanofi SA
  • Abbott
  • Pfizer Inc.
  • CombiMatrix Corporation
  • GE Healthcare
  • Celgene Corporation
  • Johnson & Johnson Services Inc.
  • Luminex Corporation
  • Merck & Company Inc.
  • Nanosphere Inc.  

Market Segmentation

 By Modality

  • Treatments
  • Diagnostics

By Application

  • Drug Delivery
  • Diagnostic Imaging
  • Vaccines
  • Regenerative Medicine
  • Implants
  • Others 

By Indication

  • Oncological Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Orthopedic Diseases
  • Neurological Diseases
  • Urological Diseases
  • Ophthalmological Diseases
  • Immunological Diseases
  • Others

By Nanomolecule Type

  • Nanoparticles
    • Metal & Metal Oxide Nanoparticles
    • Liposomes
    • Polymers & polymer drug conjugates
    • Hydrogel nanoparticles
    • Dendrimers
    • Inorganic nanoparticles
  • Nanoshells
  • Nanotubes
  • Nanodevices

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Research Methodology

The research methodology adopted by analysts for compiling the global nanomedicine report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global nanomedicine market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Nanomedicine Market 

5.1. COVID-19 Landscape: Nanomedicine Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Nanomedicine Market, By Modality

8.1. Nanomedicine Market, by Modality Type, 2022-2030

8.1.1. Treatments

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Diagnostics

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Nanomedicine Market, By Application

9.1. Nanomedicine Market, by Application, 2022-2030

9.1.1. Drug Delivery

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Diagnostic Imaging

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Vaccines

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Regenerative Medicine

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Implants

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.6. Others

9.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Nanomedicine Market, By Indication Type 

10.1. Nanomedicine Market, by Indication Type, 2022-2030

10.1.1. Oncological Diseases

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Infectious Diseases

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Cardiovascular Diseases

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Orthopedic Diseases

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Neurological Diseases

10.1.5.1. Market Revenue and Forecast (2017-2030)

10.1.6. Urological Diseases

10.1.6.1. Market Revenue and Forecast (2017-2030)

10.1.7. Others

10.1.7.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Nanomedicine Market, By Nanomolecule Type 

11.1. Nanomedicine Market, by Nanomolecule Type, 2022-2030

11.1.1. Nanoparticles

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Nanoshells

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Nanotubes

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Nanodevices

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Nanomedicine Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Modality (2017-2030)

12.1.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.1.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Modality (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Modality (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Modality (2017-2030)

12.2.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.2.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Modality (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Modality (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Modality (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Modality (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Modality (2017-2030)

12.3.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.3.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Modality (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Modality (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Modality (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Modality (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Modality (2017-2030)

12.4.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.4.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Modality (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Modality (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Modality (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Modality (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Modality (2017-2030)

12.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.5.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Modality (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Modality (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Indication Type (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)

Chapter 13. Company Profiles

13.1. Sanofi SA

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Abbott

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Pfizer Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. CombiMatrix Corporation

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. GE Healthcare

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Celgene Corporation

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Johnson & Johnson Services Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Luminex Corporation

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Merck & Company Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Nanosphere Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

 

Tags:

Post a Comment

0 Comments